US pharmaceutical giant Eli Lilly has announced an additional $4.5 billion (€4.1bn) investment across two of its three Lebanon, Indiana sites, bringing the company's total Indiana capital expansion commitments since 2020 to more than $21 billion (€19.3bn). Reuters reported on the announcement, confirmed on 6 May 2026.

The investment covers two facilities: Lilly Lebanon Advanced Therapies, the company's first dedicated genetic medicine manufacturing facility, which opened on 6 May 2026, and Lilly Lebanon API, a future active pharmaceutical ingredient site set to open in 2027 as the largest API production site in US history.

The investment will incorporate new process designs and technologies at both sites, with the Lilly Lebanon API facility representing manufacturing processes for which there is no established commercial precedent.

Lilly Lebanon Advanced Therapies is designed to support both clinical and commercial production of genetic medicines. Planned production at the Lebanon campus also includes Foundayo and retatrutide, an oral weight-loss medicine currently in late-stage development.

The additional $4.5 billion (€4.1bn) commitment was prompted by Lilly's evolving pipeline and anticipated demand for its medicines. Since 2020, the company has committed more than $50 billion (€46.1bn) in US capital expansion, underscoring the scale of its domestic manufacturing build-out.

Both the genetic medicine facility and the API site are located at the LEAP Research and Innovation District in Lebanon, approximately 27 miles northwest of Indianapolis, where Lilly is headquartered.

The investment positions Lilly to significantly expand its manufacturing capacity across obesity, diabetes, and genetic medicines as global demand for the company's treatments continues to grow at pace.

Explore the full details of Eli Lilly's Indiana manufacturing commitment here.